Rapid Dose Therapeutics Cash Flow Statement

Financials in millions CAD. Fiscal year is March - February.

Millions CAD. Fiscal year is Mar - Feb.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Feb '26 Feb 28, 2026	Feb '25 Feb 28, 2025	Feb '24 Feb 29, 2024	Feb '23 Feb 28, 2023	Feb '22 Feb 28, 2022
Net Income	-3.39	-5.4	-4.31	-3.81	-8.49
Depreciation & Amortization	0.51	0.24	0.62	0.63	0.77
Asset Writedown & Restructuring Costs	-	-	-	-	4.08
Stock-Based Compensation	0.37	1.42	0.16	0.71	1.7
Provision & Write-off of Bad Debts	-	-	-0.01	0.02	-
Other Operating Activities	1.07	1.08	0.75	0.13	0.15
Change in Accounts Receivable	0.13	-0.08	-0.07	0.02	0.2
Change in Inventory	0.09	-0.11	0.01	0.08	-0.04
Change in Accounts Payable	0.94	1.64	0.62	1.31	-0.47
Change in Unearned Revenue	-	-	-0.01	-0.01	-0.88
Change in Other Net Operating Assets	0	0.07	-0.06	0.06	-0.02
Operating Cash Flow	-0.27	-1.15	-2.29	-0.86	-3
Capital Expenditures	-0	-0.01	-	-	-0.04
Sale of Property, Plant & Equipment	-	-	-	-	0
Cash Acquisitions	-	-	-	-	1.89
Investing Cash Flow	-0	-0.01	-	-	1.85
Short-Term Debt Issued	0.19	-	0.43	0.81	0.13
Long-Term Debt Issued	0.46	-	1.83	0.2	-
Total Debt Issued	0.65	-	2.26	1.01	0.13
Short-Term Debt Repaid	-	-0.25	-0.7	-	-
Long-Term Debt Repaid	-0.39	-0.13	-0.34	-0.31	-0.29
Total Debt Repaid	-0.39	-0.38	-1.04	-0.31	-0.29
Net Debt Issued (Repaid)	0.26	-0.38	1.22	0.7	-0.16
Issuance of Common Stock	-	1.39	1.3	0.15	1.28
Other Financing Activities	-	-	-0.09	-	-
Financing Cash Flow	0.26	1.01	2.43	0.86	1.13
Foreign Exchange Rate Adjustments	-	-	-	0	-0.02
Net Cash Flow	-0.01	-0.14	0.13	-0.01	-0.04
Free Cash Flow	-0.27	-1.15	-2.29	-0.86	-3.04
Free Cash Flow Margin	-9.78%	-55.27%	-224.91%	-120.27%	-173.52%
Free Cash Flow Per Share	-0.00	-0.01	-0.02	-0.01	-0.03
Cash Interest Paid	-	-	-	0.08	0.07
Levered Free Cash Flow	-0.09	-0.21	-1.89	0.55	-1.55
Unlevered Free Cash Flow	0.67	0.56	-1.48	0.72	-1.47
Change in Working Capital	1.16	1.52	0.49	1.46	-1.21